These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

434 related items for PubMed ID: 28666800

  • 81. L-dopa-Dependent Effects of GLP-1R Agonists on the Survival of Dopaminergic Cells Transplanted into a Rat Model of Parkinson Disease.
    Elabi OF, Davies JS, Lane EL.
    Int J Mol Sci; 2021 Nov 16; 22(22):. PubMed ID: 34830228
    [Abstract] [Full Text] [Related]

  • 82.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 83. Nei-like 1 inhibition results in motor dysfunction and promotes inflammation in Parkinson's disease mice model.
    Xue B, Xiao W, Tian H.
    Biochem Biophys Res Commun; 2020 Jan 01; 521(1):245-251. PubMed ID: 31653343
    [Abstract] [Full Text] [Related]

  • 84. Antidiabetic agents as a novel treatment for Alzheimer's and Parkinson's disease.
    Nowell J, Blunt E, Gupta D, Edison P.
    Ageing Res Rev; 2023 Aug 01; 89():101979. PubMed ID: 37328112
    [Abstract] [Full Text] [Related]

  • 85.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 86. Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice.
    Jojima T, Uchida K, Akimoto K, Tomotsune T, Yanagi K, Iijima T, Suzuki K, Kasai K, Aso Y.
    Atherosclerosis; 2017 Jun 01; 261():44-51. PubMed ID: 28445811
    [Abstract] [Full Text] [Related]

  • 87.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 88.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 89.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 90. A New Treatment Strategy for Parkinson's Disease through the Gut-Brain Axis: The Glucagon-Like Peptide-1 Receptor Pathway.
    Kim DS, Choi HI, Wang Y, Luo Y, Hoffer BJ, Greig NH.
    Cell Transplant; 2017 Sep 01; 26(9):1560-1571. PubMed ID: 29113464
    [Abstract] [Full Text] [Related]

  • 91.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 92. Beyond insulin: The Intriguing role of GLP-1 in Parkinson's disease.
    Verma A, Goyal A.
    Eur J Pharmacol; 2024 Nov 05; 982():176936. PubMed ID: 39182542
    [Abstract] [Full Text] [Related]

  • 93.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 94.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 95. Tanshinone I selectively suppresses pro-inflammatory genes expression in activated microglia and prevents nigrostriatal dopaminergic neurodegeneration in a mouse model of Parkinson's disease.
    Wang S, Jing H, Yang H, Liu Z, Guo H, Chai L, Hu L.
    J Ethnopharmacol; 2015 Apr 22; 164():247-55. PubMed ID: 25666429
    [Abstract] [Full Text] [Related]

  • 96.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 97. Nobiletin treatment improves motor and cognitive deficits seen in MPTP-induced Parkinson model mice.
    Yabuki Y, Ohizumi Y, Yokosuka A, Mimaki Y, Fukunaga K.
    Neuroscience; 2014 Feb 14; 259():126-41. PubMed ID: 24316474
    [Abstract] [Full Text] [Related]

  • 98. Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide dual receptor agonist DA-CH5 is superior to exendin-4 in protecting neurons in the 6-hydroxydopamine rat Parkinson model.
    Zhang LY, Jin QQ, Hölscher C, Li L.
    Neural Regen Res; 2021 Aug 14; 16(8):1660-1670. PubMed ID: 33433498
    [Abstract] [Full Text] [Related]

  • 99. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.
    Willard FS, Douros JD, Gabe MB, Showalter AD, Wainscott DB, Suter TM, Capozzi ME, van der Velden WJ, Stutsman C, Cardona GR, Urva S, Emmerson PJ, Holst JJ, D'Alessio DA, Coghlan MP, Rosenkilde MM, Campbell JE, Sloop KW.
    JCI Insight; 2020 Sep 03; 5(17):. PubMed ID: 32730231
    [Abstract] [Full Text] [Related]

  • 100. Glucagon-like peptide 1 and glucose-dependent insulinotropic peptide hormones and novel receptor agonists protect synapses in Alzheimer's and Parkinson's diseases.
    Hölscher C.
    Front Synaptic Neurosci; 2022 Sep 03; 14():955258. PubMed ID: 35965783
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.